Your browser is no longer supported. Please, upgrade your browser.
Compugen Ltd.
Index- P/E- EPS (ttm)-0.39 Insider Own12.00% Shs Outstand83.68M Perf Week-3.33%
Market Cap567.28M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float83.56M Perf Month-14.27%
Income-32.50M PEG- EPS next Q-0.12 Inst Own49.20% Short Float8.75% Perf Quarter-23.60%
Sales2.00M P/S283.64 EPS this Y13.10% Inst Trans0.01% Short Ratio7.22 Perf Half Y-46.81%
Book/sh1.32 P/B5.05 EPS next Y-31.40% ROA-23.30% Target Price- Perf Year-54.41%
Cash/sh- P/C- EPS next 5Y- ROE-26.70% 52W Range6.57 - 19.90 Perf YTD-44.92%
Dividend- P/FCF- EPS past 5Y1.40% ROI-26.30% 52W High-66.48% Beta2.32
Dividend %- Quick Ratio10.60 Sales past 5Y-26.40% Gross Margin97.00% 52W Low1.52% ATR0.43
Employees68 Current Ratio10.60 Sales Q/Q- Oper. Margin- RSI (14)36.37 Volatility4.92% 5.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.70% Profit Margin- Rel Volume0.49 Prev Close6.78
ShortableYes LT Debt/Eq0.00 EarningsJul 28 BMO Payout- Avg Volume1.01M Price6.67
Recom1.40 SMA20-12.53% SMA50-13.65% SMA200-37.44% Volume493,289 Change-1.62%
May-26-20Resumed JMP Securities Mkt Outperform $18
May-13-20Initiated Stifel Buy $19
May-07-20Initiated SVB Leerink Outperform
Apr-22-20Initiated ROTH Capital Buy $28
Mar-24-20Initiated SunTrust Buy $16
Jan-16-20Initiated Cantor Fitzgerald Overweight $10
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Jul-19-21 07:00AM  
Jul-15-21 07:00AM  
Jul-14-21 07:00AM  
Jul-09-21 02:42AM  
Jun-30-21 07:00AM  
Jun-29-21 07:00AM  
Jun-08-21 08:02AM  
Jun-01-21 07:00AM  
May-22-21 09:00AM  
May-13-21 08:30PM  
May-11-21 07:00AM  
May-10-21 07:00AM  
May-03-21 07:00AM  
Apr-29-21 07:00AM  
Apr-27-21 07:00AM  
Mar-11-21 12:42AM  
Mar-09-21 07:00AM  
Mar-08-21 07:00AM  
Feb-26-21 05:00PM  
Feb-25-21 08:21AM  
Feb-22-21 07:00AM  
Feb-16-21 07:00AM  
Jan-23-21 11:30PM  
Jan-10-21 02:01AM  
Dec-23-20 07:00AM  
Dec-14-20 09:55AM  
Nov-11-20 06:09AM  
Nov-10-20 07:00AM  
Nov-05-20 10:01PM  
Nov-03-20 12:19PM  
Nov-02-20 07:00AM  
Oct-28-20 12:55PM  
Oct-27-20 07:00AM  
Oct-26-20 08:45AM  
Oct-22-20 07:00AM  
Sep-30-20 07:15AM  
Sep-12-20 10:59AM  
Sep-09-20 01:35AM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-28-20 07:00AM  
Jul-31-20 02:31AM  
Jul-30-20 07:00AM  
Jul-16-20 07:00AM  
Jul-14-20 03:35PM  
Jun-22-20 02:40PM  
Jun-01-20 07:00AM  
May-27-20 07:00AM  
May-20-20 07:02AM  
May-18-20 08:46AM  
May-13-20 09:48AM  
May-08-20 02:39PM  
May-06-20 10:00PM  
May-04-20 11:57AM  
Apr-30-20 12:00PM  
Apr-27-20 06:05AM  
Apr-24-20 10:50AM  
Apr-23-20 07:00AM  
Apr-22-20 08:22AM  
Apr-20-20 07:00AM  
Apr-14-20 07:00AM  
Apr-06-20 07:00AM  
Mar-17-20 07:00AM  
Mar-12-20 06:05AM  
Mar-11-20 04:01PM  
Mar-10-20 10:00AM  
Mar-09-20 07:10AM  
Feb-20-20 07:05AM  
Feb-10-20 07:58AM  
Feb-07-20 07:00AM  
Feb-04-20 07:00AM  
Jan-29-20 08:30AM  
Jan-16-20 07:47PM  
Jan-09-20 07:00AM  
Jan-08-20 07:00AM  
Dec-23-19 08:04PM  
Dec-20-19 07:00AM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-03-19 12:00PM  
Nov-11-19 07:00AM  
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.